Financial Counselors Inc. Has $391,000 Stock Position in Sanofi (NASDAQ:SNY)

Financial Counselors Inc. increased its position in shares of Sanofi (NASDAQ:SNY) by 11.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,858 shares of the company’s stock after buying an additional 820 shares during the quarter. Financial Counselors Inc.’s holdings in Sanofi were worth $391,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in SNY. Fairfield Bush & CO. acquired a new position in Sanofi during the 1st quarter worth approximately $26,000. Bank of New York Mellon Corp increased its holdings in Sanofi by 31.3% during the 1st quarter. Bank of New York Mellon Corp now owns 440,646 shares of the company’s stock worth $22,623,000 after purchasing an additional 105,046 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its holdings in Sanofi by 12.9% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 24,613 shares of the company’s stock worth $1,264,000 after purchasing an additional 2,805 shares in the last quarter. Yousif Capital Management LLC increased its holdings in Sanofi by 45.2% during the 1st quarter. Yousif Capital Management LLC now owns 42,041 shares of the company’s stock worth $2,158,000 after purchasing an additional 13,095 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Sanofi by 0.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 300,009 shares of the company’s stock worth $15,402,000 after purchasing an additional 1,391 shares in the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Performance

SNY stock opened at $45.93 on Friday. The firm has a market cap of $116.18 billion, a PE ratio of 19.46, a P/E/G ratio of 1.72 and a beta of 0.61. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The business has a 50 day moving average of $47.60 and a 200-day moving average of $48.84. Sanofi has a 12-month low of $42.63 and a 12-month high of $57.82.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by ($0.05). The business had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. Sanofi had a net margin of 12.56% and a return on equity of 27.47%. As a group, sell-side analysts expect that Sanofi will post 4.16 earnings per share for the current year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be paid a $1.478 dividend. This is an increase from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. This represents a yield of 2.98%. Sanofi’s dividend payout ratio is presently 58.47%.

Analyst Upgrades and Downgrades

SNY has been the subject of a number of recent research reports. TheStreet lowered Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Finally, Morgan Stanley initiated coverage on Sanofi in a report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $55.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.